High-risk neuroblastoma (HRNB) remains a major cause of cancer-related deaths in children despite intensive multimodal therapy. Standard regimens rely on multi-agent chemotherapy with platinum-based drugs such as cisplatin, which contribute substantially to acute and long-term treatment toxicities. Strategies that maintain or increase anti-tumor efficacy while enabling chemotherapy dose reduction are therefore of high clinical interest.
MicroRNA (miR)-based therapeutics are attractive because single miRs can modulate multiple oncogenic pathways simultaneously, potentially producing broad anti-cancer effects. However, most prior miR therapeutics have used chemically synthesized molecules, which the authors note suffer from manufacturing inconsistency and limited in vivo stability. These limitations have constrained clinical translation.
To overcome shortcomings of chemically synthesized miRs, the study used biologically produced, tRNA/pre-miR containing bioengineered microRNAs (bioRNAs). These constructs encode either miR-124 or miR-34a and are produced biologically to improve consistency and in vivo stability relative to chemically synthesized counterparts. The authors evaluated these bioRNAs across molecularly distinct HRNB models to determine therapeutic potential and interaction with cisplatin.
Both miR-124 and miR-34a bioRNAs significantly reduced neuroblastoma cell viability in vitro across multiple HRNB cell lines. The study reports that bioRNA monotherapy suppressed viability, indicating that these miRs have intrinsic anti-tumor activity in neuroblastoma models of different molecular subtypes. The authors emphasize the broad activity across distinct HRNB models rather than single-line specificity.
Proteomic analyses performed on treated cells revealed distinct, preferential biological programs induced by each bioRNA. miR-124 bioRNA preferentially induced proteins and pathways associated with neuronal differentiation, consistent with promoting a more differentiated cellular phenotype. In contrast, miR-34a bioRNA preferentially activated apoptotic signaling pathways, aligning with direct induction of cell death mechanisms. These complementary effects suggest different but potentially synergistic modes of anti-neuroblastoma action.
When combined with cisplatin, both bioRNAs produced robust synergy in multiple HRNB cell lines. The combination enhanced apoptotic responses while also promoting differentiation-associated phenotypes observed with miR-124. The authors report that bioRNA co-treatment increased the efficacy of cisplatin beyond that of either agent alone in vitro, supporting a role for bioRNAs as cisplatin sensitizers.
In xenograft models representing different HRNB subtypes, both bioRNAs suppressed tumor growth as single agents. The most pronounced anti-tumor responses were observed when bioRNA therapy was combined with low-dose cisplatin. Across multiple xenograft models, the combination consistently produced stronger tumor control than bioRNA monotherapy.
A key finding reported by the authors is that pairing low-dose cisplatin with bioRNA therapy often achieved tumor control comparable to, or exceeding, that achieved with high-dose cisplatin monotherapy in the models tested. The combination regimens maintained favorable tolerability in these preclinical studies, suggesting the potential to reduce platinum-associated toxicities while preserving or improving anti-tumor efficacy. The authors frame this as supporting a dose-reduction strategy when bioRNA sensitizers are used alongside chemotherapy.
The findings position biologically produced bioRNA constructs encoding miR-124 and miR-34a as promising cisplatin sensitizers for HRNB. By enhancing chemotherapy efficacy and promoting complementary biological programs (differentiation and apoptosis), bioRNA-based combinations may enable lower chemotherapy doses and reduced long-term toxicities in pediatric patients.
Important contextual notes from the source: this work is reported as a preprint and has not undergone peer review. The article provides experimental and supplementary data supporting the in vitro proteomic findings and in vivo xenograft results, but details such as dosing regimens, sample sizes, and specific statistical outcomes are contained in the full preprint and supplementary materials. Those methodological and quantitative details should be reviewed directly in the source for decision-making or clinical translation planning.
Overall, the reported results support further preclinical development and structured evaluation of bioRNA plus reduced-dose cisplatin regimens, with the caveat that clinical translation will require rigorous peer review, reproducibility testing, safety assessment, and formal clinical trials.